Education
About Us
Working with TipRanks
Follow Us
Syros Pharmaceuticals (SYRS)
OTHER OTC:SYRS
SYRS Stock Chart & Stats
Day’s Range― - ―
52-Week Range<$0.01 - $6.93
Previous CloseN/A
Volume1.14M
Average Volume (3M)121.72K
Market Cap
$268.32K
Enterprise Value$2.25M
Total Cash (Recent Filing)$58.27M
Total Debt (Recent Filing)$60.23M
Price to Earnings (P/E)―
Beta2.20
Next Earnings
Jul 31, 2025EPS Estimate
-0.24Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.38
Shares Outstanding26,832,457
10 Day Avg. Volume69,824
30 Day Avg. Volume121,719
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)-0.04
Price to Sales (P/S)0.00
P/FCF Ratio>-0.01
Enterprise Value/Market Cap8.38
Enterprise Value/Revenue0.10
Enterprise Value/Gross Profit-2.55
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$1.00Price Target Upside9900.00% Upside
Rating ConsensusHold
Number of Analyst Covering0
Syros Pharmaceuticals News
PremiumPre-Earnings
Is SYRS a Buy, Before Earnings?
PremiumPre-Earnings
Is SYRS a Buy, Before Earnings?
PremiumCompany Announcements
Syros Pharmaceuticals Delists from Nasdaq Amid Restructuring
Bulls Say, Bears Say
Bulls Say
Drug TolerabilityThe tamibarotene/azacitidine combination was well-tolerated, with an adverse event profile reflective of prior clinical trials.
Bears Say
Analyst OpinionSyros Pharmaceuticals has been downgraded from Buy to Neutral with a price target reduced from $6 to $1.
Clinical TrialsThe failure of SELECT-MDS-1 ends Syros' last active clinical program and triggers an event of default under the terms of the company's secured loan facility with Oxford Finance.
Financial PerformanceThe stock traded down about 86% in the aftermarket, reflecting a significant decline in valuation.
Options Prices
Currently, No data available
---
Ownership Overview
9.99% Insiders
0.63% Mutual Funds
0.52% Other Institutional Investors
88.86% Public Companies and Individual Investors
SYRS FAQ
What was Syros Pharmaceuticals’s price range in the past 12 months?
Syros Pharmaceuticals lowest stock price was <$0.01 and its highest was $6.93 in the past 12 months.
What is Syros Pharmaceuticals’s market cap?
Syros Pharmaceuticals’s market cap is $268.32K.
When is Syros Pharmaceuticals’s upcoming earnings report date?
Syros Pharmaceuticals’s upcoming earnings report date is Jul 31, 2025 which is in 11 days.
How were Syros Pharmaceuticals’s earnings last quarter?
Syros Pharmaceuticals released its earnings results on May 01, 2025. The company reported -$0.38 earnings per share for the quarter, the consensus estimate of -$0.38 by $0.
Is Syros Pharmaceuticals overvalued?
According to Wall Street analysts Syros Pharmaceuticals’s price is currently Undervalued.
Does Syros Pharmaceuticals pay dividends?
Syros Pharmaceuticals does not currently pay dividends.
What is Syros Pharmaceuticals’s EPS estimate?
Syros Pharmaceuticals’s EPS estimate is -0.24.
How many shares outstanding does Syros Pharmaceuticals have?
Syros Pharmaceuticals has 26,832,457 shares outstanding.
What happened to Syros Pharmaceuticals’s price movement after its last earnings report?
Syros Pharmaceuticals reported an EPS of -$0.38 in its last earnings report, expectations of -$0.38. Following the earnings report the stock price went up 33.333%.
Which hedge fund is a major shareholder of Syros Pharmaceuticals?
Currently, no hedge funds are holding shares in SYRS
Company Description
Syros Pharmaceuticals
Syros Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of treatments for cancer and monogenic diseases, and building a pipeline of gene control medicines. The company's lead product candidates are Tamibarotene, a selective retinoic acid receptor alpha agonist, which is in Phase III clinical trial for genomically defined subset of patients with myelodysplastic syndrome and Phase II clinical trial for patients with acute myeloid leukemia; SY-2101, a novel oral form of arsenic trioxide for treating patients with acute promyelocytic leukemia; and SY-5609, a cyclin-dependent kinase 7 inhibitor, which is in a Phase I clinical trial in patients with select advanced solid tumors. It has target discovery, research collaboration, and option agreement with Incyte Corporation to identify therapeutic targets with a focus on myeloproliferative neoplasms; and a license agreement with TMRC Co. Ltd. for the development and commercialization of tamibarotene. The company was formerly known as LS22, Inc. and changed its name to Syros Pharmaceuticals, Inc. in August 2012. Syros Pharmaceuticals, Inc. was incorporated in 2011 and is headquartered in Cambridge, Massachusetts.
Technical Analysis
Biodexa Pharmaceuticals
―
Scorpius Holdings
―
TNF Pharmaceuticals
―
Hepion Pharmaceuticals
―
Windtree Therapeutics
―